Antineoplastic and Biologic Therapies Flashcards
6 cards from real CRNI practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 6 Antineoplastic and Biologic Therapies flashcards as text
Which vesicant chemotherapy agent requires immediate intervention if extravasation occurs during IV infusion?
Answer: Doxorubicin
Doxorubicin is a vesicant that can cause severe tissue necrosis if extravasation occurs, requiring immediate intervention including stopping the infusion and applying cold compresses.
When administering biologic response modifiers, which nursing assessment is MOST critical during the first 30 minutes?
Answer: Monitoring for anaphylactic reactions
Biologic agents such as monoclonal antibodies carry the highest risk of infusion reactions and anaphylaxis during the first 30 minutes of administration.
What is the recommended action when a patient receiving a cytotoxic infusion reports burning at the IV site?
Answer: Stop the infusion immediately and assess the site
Burning at the IV site during cytotoxic infusion suggests possible extravasation, requiring immediate cessation of the infusion and thorough site assessment.
Which personal protective equipment (PPE) is required when handling antineoplastic agents according to current INS standards?
Answer: Double chemotherapy-tested gloves, gown, and face shield
Current standards require double gloving with chemotherapy-tested gloves, a protective gown, and face/eye protection when handling antineoplastic agents to prevent occupational exposure.
A patient is prescribed a targeted therapy infusion. Which laboratory value should be monitored MOST closely during treatment?
Answer: Complete blood count with differential
Targeted therapies frequently cause myelosuppression, making CBC with differential essential for monitoring neutropenia, thrombocytopenia, and anemia.
What is the maximum recommended time frame for use of a closed-system transfer device (CSTD) when preparing hazardous drugs?
Answer: Within the beyond-use date specified by the manufacturer
CSTDs must be used within the manufacturer-specified beyond-use date to ensure containment integrity and prevent hazardous drug exposure.